U
PRTA icon

UBS’s Prothena Corp PRTA Stock Holding History

UBS’s Portfolio PRTA Stock Details PRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100
Closed -$2K – 10666
2014
Q2 		$2K Buy
+100
New +$2.5K ﹤0.01% 10055

Other funds holding PRTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS's PRTA Position: Q3 2014 in Review

UBS increased its Prothena Corp (PRTA) stake by 6% in Q3 2014, buying an estimated $8.39K and bringing the position to 6,963 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #5473.

UBS first reported a position in PRTA in Q2 2013 and has held it in 6 quarters since. The position peaked at $179K in Q1 2014. 127 funds tracked by Wall St. Rank hold PRTA as of Q3 2014.

  • UBS held 6,963 shares of Prothena Corp worth $154K as of Q3 2014.
  • UBS bought 396 Prothena Corp shares in Q3 2014, an estimated $8.39K.
  • Prothena Corp made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5473 holding.
  • UBS first reported a position in Prothena Corp in Q2 2013 and has held it in 6 quarters since.
  • UBS's Prothena Corp position peaked at $179K in Q1 2014.
  • 127 funds tracked by Wall St. Rank held Prothena Corp as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.